Brian Buntz

St. Jude Medical: +9%

Posted in by Brian Buntz on September 2, 2015
St. Jude Medical: +9% St. Jude Medical has since its stock increase steadily this year, recently rising 5% to $72.80 last Thursday morning, after a rumor that Abbott Laboratories was planning on bidding to acquire the firm, which Abbott denied.  The company is increasing the size of i... Continue

Essilor International: +7%

Posted in by Brian Buntz on September 2, 2015
Essilor International: +7%Recently featured in our who's hiring and who's firing roundup, French ophthalmologic specialist Essilor clearly belongs in the former category. The company has added 23,273 employees in the past five years. The company's stock has increased from the €48 range five years ... Continue

Fresenius Medical Care: +10%

Posted in by Brian Buntz on September 2, 2015
Fresenius Medical Care: +10% Fresenius (Bad Homburg, Germany) has had a solid first six months of the year with its stock opening the year around $35 and eventually hitting $44 in late July. Perhaps the tide is turning. Its stock has been falling recently and it closed the day on September... Continue

Edwards Lifesciences: +11%

Posted in by Brian Buntz on September 2, 2015
Edwards Lifesciences: +11%Edwards has certainly had meteoric growth since the beginning of 2014, with its stock rising from the mid-$60 range then to the $155 range in July of this year. Now trading at about $135 per share, Edwards has benefitted from solid sales of its Sapien lines of transcatheter... Continue

Terumo Corp.: +13%

Posted in by Brian Buntz on September 2, 2015
Terumo Corp.: +13%Like many medtech companies that are faring well in 2015, Terumo has a strong cardiovascular business, having acquired some of their assets in this area from 3M in 1999 and UK-based Vascutek Ltd in 2002. Since then, the company’s share price has grown steadily for the most part, ... Continue

Boston Scientific: +26.34%

Posted in by Brian Buntz on September 2, 2015
In the past couple of years, Boston Scientific has made good on CEO Michael Mahoney’s promise to turn around years of sluggish performance. The company’s stock has roughly tripled in value since late 2011, and grew steadily in 2015 thus far. In fact, a report from Evaluate Medtech found that the... Continue

Strong Dollar Puts Brakes on Medtech Exports

Posted in by Brian Buntz on September 2, 2015
Currency fluctuations have had negative effects on the business of U.S.-based medical firms as well as European companies, according to an Emergo survey. Brian BuntzStarting about one year ago, the U.S. dollar began to strengthen in value compared to the euro and other currencies. For American ... Continue

Hologic: 45%

Posted in by Brian Buntz on September 2, 2015
Mammography innovation appears to be driving stellar growth for Hologic, which saw its stock value rise 45% during the first nine months of 2015. The Bedford, MA–based medtech company says it has been seeing accelerated adoption of its FDA-approved Genius 3D mammography systems (shown above), with... Continue